The results showed that PCa patients in the high-risk group were more susceptible to bryostatin.1, docetaxel, gefitinib, methotrexate, paclitaxel, and vinblastine, whereas patients in the low-risk group were more susceptible to AKT inhibitor VIII, bexarotene, bicalutamide, doxorubicin, gemcitabine, and vinorelbine (Figure 10). The gene discussed is AKT1; the disease is posterior cortical atrophy.